Allergy Therapeutics reports accelerated revenue growth in its second half

Impact · against what's priced in

Allergy Therapeutics sees a positive catalyst from accelerating revenue growth and double-digit guidance for 2027. Cordiant Digital Infrastructure's move toward full capacity at its Hudson Interxchange facility provides a steady increase in asset value.

AGY+0.60

No priced-in read yet

In context

Revenue growth acceleration to 12% in the second half and the guide for double-digit growth in 2027 suggests improving momentum for Grassmuno.

Read from the article alone

• guidance▲23%
• healthcare▲17%
• revenue growth▲7%
• biotech
• AGY
• CORD
• immunotherapy